Skip to content
All Sections
Subscribe Now
62°F
Saturday, September 28th 2024
e-Edition
Home Page
Close Menu
News
News
Crime and Public Safety
Investigative Reporting
Politics
Health
Environment
Business
Best Reviews
Housing
Jobs
Local News
Local News
Long Beach
Los Angeles
Los Angeles County
Sports
Sports
High School Sports
Chargers
Rams
Lakers
Clippers
Dodgers
Angels
College Sports
UCLA Sports
USC Sports
Long Beach State sports
Kings
Ducks
Olympics
Boxing/MMA
Soccer
Horse Racing
Things To Do
Things To Do
Restaurants Food and Drink
Movies
Music + Concerts
Theater
TV and Streaming
Home + Garden
Travel
Amusement Parks
Comics
Puzzles
Events
Obituaries
Obituaries
News Obituaries
Place an Obituary
Opinion
Opinion
Editorials
Opinion Columns
Commentary
Letters to the Editor
Editorial Board
Endorsements
The Grunion
The Grunion
News
Education
Sports
Things to Do
Opinion
E-Edition
Advertising
Contact Us
SCNG Premium
The T.E.A.
Subscribe
Press-Telegram Store
Log In
Logout
Close Menu
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Account Settings
Contact Us
Log Out
Spoof a user
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Search
Press Telegram
62°F
Saturday, September 28th 2024
e-Edition
News
Local News
Sports
Things to Do
Obituaries
Opinion
The T.E.A.
Trending:
Latest Trump news
Man hit, killed by fire engine
Affordable senior housing opens
Westbrook Academy reopens
High School Football
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by ImmunityBio, Inc.
< Previous
1
2
Next >
ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer
September 09, 2024
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval
August 12, 2024
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer
August 06, 2024
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors
June 20, 2024
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update
June 07, 2024
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast
May 17, 2024
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®
May 07, 2024
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types
May 02, 2024
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association
April 30, 2024
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
April 25, 2024
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
April 22, 2024
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG
February 05, 2024
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million
January 02, 2024
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio to Participate in 35th Annual Piper Sandler Healthcare Conference
November 16, 2023
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
First Data for ImmunityBio’s Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor Activity
November 07, 2023
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
FDA Accepts ImmunityBio’s BLA Resubmission as Complete and Sets New PDUFA Date
October 26, 2023
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio Announces Biological License Application Resubmission for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ
October 23, 2023
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio Announces $470 Million Equity and Debt Financing From Founder, Dr. Patrick Soon-Shiong and Nant Entities
September 11, 2023
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio Names Enrique Diloné as Chief Technology Officer
August 03, 2023
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio Announces Execution of $40 Million Equity Financing with Institutional Investors
July 20, 2023
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
Phase 1 Study Indicates Allogeneic Cytokine-Induced Memory-Like Natural Killer Cells Plus N-803 May Induce Tumor Regression in Advanced Head-and-Neck Cancer Patients
July 10, 2023
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio to Participate in the Jefferies Global Healthcare Conference
May 22, 2023
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
National Multicenter Trial Opens to Study ImmunityBio’s Tri-Ad5 Cancer Vaccines Plus N-803 to Prevent Cancer in People with Lynch Syndrome
April 25, 2023
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong Delivers the Packard Lecture at Uniformed Services University
April 24, 2023
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio to Present ‘Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15R⍺Fc superagonist N-803 plus BCG’ at ASCO GU
February 16, 2023
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio Announces Execution of $50 Million Equity Financing with Multiple Institutional Investors
February 15, 2023
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio Announces Presentation at ASCO GI 2023 of Fully Enrolled Trial in Third-Line and Greater Pancreatic Cancer and Update on FDA Type B Meetings Regarding Paths to Registration
January 19, 2023
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio Announces $157 Million Financing From Nant and Institutional Investor
December 12, 2022
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio to Participate in 34th Annual Piper Sandler Healthcare Conference
November 17, 2022
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio to Participate in the Jefferies London Healthcare Conference
October 27, 2022
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close